Belimumab is indicated for:
Systemic lupus erythematosus (SLE)
Irrespective of gender only Adults (18 - 65 years old)
Belimumab is indicated as add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti-dsDNA and low complement) despite standard therapy.
For this indication, the medical literature mentions below treatments (click for details):
Treatment 1: Subcutaneous - 200 mg once weekly
Treatment 2: Intravenous - 10 mg/kg on days 0, 14 and 28 and at 4-week intervals thereafter
Active ingredient Belimumab is contraindicated in the following cases: